We have compiled a variety of clinical studies that you can receive upon request. These studies provide key evidence regarding the efficacy of therapies, pumps, CGM and more.
Use the filters to quickly find the information you need.
ADAPT study – 6 month trial results
Adults with type 1 diabetes who are treated with multiple daily injections of insulin plus intermittently scanned continuous glucose monitoring (isCGM) can have suboptimal glucose control.
We aimed to assess the efficacy of an advanced hybrid closed loop (AHCL) system compared with such therapy in this population.
In people with T1D using MDI+isCGM and with HbA1c ≥8·0%, the use of AHCL confers benefits in terms of glycaemic control and user satisfaction beyond those that can be achieved with MDI+isCGM therapy. This data supports wider and earlier access to AHCL in people with T1D not at target glucose levels.